Literature DB >> 16675763

Anticonvulsant treatment for psychiatric and seizure indications among youths.

Julie Magno Zito1, Daniel J Safer, James F Gardner, Karen Soeken, Jae Ryu.   

Abstract

OBJECTIVE: This study compared the prevalence of anticonvulsant treatment for youths with a diagnosis of a psychiatric disorder to youths with a diagnosis of a seizure disorder.
METHODS: Administrative claims from outpatient visits and prescriptions were organized for a data set of 258,472 youths who were younger than 18 years of age in a mid-Atlantic state Medicaid program and were continuously enrolled in 2000. Youths dispensed an anticonvulsant were grouped into the following ICD-9 diagnostic categories: a diagnosis of a psychiatric disorder without a seizure disorder, a diagnosis of a seizure disorder without a psychiatric disorder, and a diagnosis of both a psychiatric and a seizure disorder. Anticonvulsant use was analyzed for specific diagnostic classes by age, gender, race or ethnicity, and Medicaid eligibility categories.
RESULTS: A total of 4,522 youths in the one-year data set received an anticonvulsant (1.75 percent): 3,061 had a psychiatric disorder only, 251 had a seizure disorder only, and 611 had both psychiatric and seizure disorders. Among anticonvulsant-treated youths with diagnosis information in their records (3,923 of 4,522 youths), 81 percent had a psychiatric diagnosis and 19 percent had a seizure disorder; 71 percent of those with a seizure disorder also had a psychiatric disorder. Anticonvulsant use for seizure control was proportionally greater for those younger than five years. By contrast, a vast majority of anticonvulsant users with a psychiatric diagnosis were between five and 17 years. Among anticonvulsant-treated youths with a psychiatric diagnosis, males were approximately twice as common as females. For youths with a seizure disorder, no difference was found for gender. Mood disorders and attention-deficit hyperactivity disorder were the major psychiatric diagnoses associated with anticonvulsant use. Valproic acid products were the most commonly dispensed type of anticonvulsant.
CONCLUSIONS: Recent state Medicaid data reveal that youths who use anticonvulsants are far more likely to have a psychiatric diagnosis than a seizure diagnosis. Widespread off-label use of anticonvulsants for psychiatric disorders among youths warrants attention to ensure benefits and minimize risks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675763     DOI: 10.1176/ps.2006.57.5.681

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  5 in total

1.  Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age.

Authors:  Kimford J Meador; Gus A Baker; Nancy Browning; Morris J Cohen; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring
Journal:  Brain       Date:  2011-01-11       Impact factor: 13.501

Review 2.  Annual Research Review: New frontiers in developmental neuropharmacology: can long-term therapeutic effects of drugs be optimized through carefully timed early intervention?

Authors:  Susan L Andersen; Carryl P Navalta
Journal:  J Child Psychol Psychiatry       Date:  2011-02-10       Impact factor: 8.982

3.  Controversies concerning the diagnosis and treatment of bipolar disorder in children.

Authors:  Erik Parens; Josephine Johnston
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-03-10       Impact factor: 3.033

4.  Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands.

Authors:  N W van de Vrie-Hoekstra; T W de Vries; P B van den Berg; O F Brouwer; L T W de Jong-van den Berg
Journal:  Eur J Clin Pharmacol       Date:  2008-07-10       Impact factor: 2.953

5.  Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.

Authors:  Julie M Zito; Albert T Derivan; Christopher J Kratochvil; Daniel J Safer; Joerg M Fegert; Laurence L Greenhill
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-09-15       Impact factor: 3.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.